- AdventHealth Research Institute
Janisette Rivera-Rollins, a sixth-grade teacher and mother of two from Central Florida, never imagined that a clinical trial would change the course of her life. Diagnosed with triple-negative breast cancer (TNBC) in 2022 — a particularly aggressive and hard-to-treat form of the disease — she endured months of traditional chemotherapy, immunotherapy, surgery, and radiation. While those treatments shrank her tumor, they didn’t eliminate it. Then came a new opportunity: a clinical trial testing an investigational drug called datopotamab deruxtecan at AdventHealth Cancer Institute. After much prayer and with the support of her care team, Janisette enrolled — becoming the first Central Florida participant in this global study. Just five months later, on her 34th birthday, she was declared cancer-free.
Now being closely monitored by Dr. Wassim McHayleh and his team, Janisette’s story represents a promising future in cancer care. The drug she received belongs to a new class of therapies known as antibody-drug conjugates, which target cancer cells directly to maximize effectiveness while minimizing side effects. As the trial continues to enroll patients across the region, researchers hope this treatment may set a new standard for TNBC, a disease that disproportionately affects younger women and women of color. For Janisette — and the many patients who will follow — it’s more than a clinical advancement; it’s a second chance at life. Read the full story by clicking the button below.
Recent News
Alcohol, Marijuana and Type 1 Diabetes:
Whether it's a backyard barbecue, a football game or dinner with friends, alcohol and marijuana are common parts of social life. For people with Type 1 diabetes (T1D), understanding how they affect...
GLP-1 Medications: The Next Chapter in Diabetes Care
Ozempic®. Wegovy®. Zepbound®. Just a few years ago, most people had never heard these names. Today, they're among the most talked-about medications in the world. While much of the public conversation...
Q&A: Alcohol, Marijuana and Type 1 Diabetes
A Conversation with Daria Igudesman, PhD, RD, Postdoctoral Research Fellow, AdventHealth Translational Research Institute.
The Science That Moves Medicine Forward:
Have you ever wondered how breakthrough medicines are developed, how doctors determine the most effective treatments, or how healthcare continues to advance? The answer lies in clinical research—the...
Meet Jawanda Thacker: Helping Connect Today's Volunteers to Tomorrow's Medical Breakthroughs
Meet Jawanda Thacker: Helping Connect Today's Volunteers to Tomorrow's Medical Breakthroughs
Six Breakthroughs Shaping the Future of Diabetes Care
Several members of the AdventHealth Translational Research Institute (TRI) team traveled to New Orleans in June to attend the American Diabetes Association's (ADA) 2026 Scientific Sessions, where more...
AHRI Investigator Receives Prestigious American Diabetes Association Junior Faculty Development Award
The AdventHealth Translational Research Institute (TRI) is proud to announce that Dr. Justine Mucinski has received an American Diabetes Association (ADA) Junior Faculty Development Award.
Dr. Richard Pratley Featured in Nature Medicine for Breakthrough Obesity Research
Dr. Richard E. Pratley, senior investigator at the AdventHealth Translational Research Institute, has been featured as the corresponding author of a newly published study in Nature Medicine, one of...
Dr. Sparks Participates in LIMNA’s 17th Annual Metabolism and Aging Symposium
AdventHealth researcher Dr. Lauren Sparks recently had the honor of participating in LIMNA’s 17th Annual Symposium on “Metabolism and Aging” at the Olympic Museum in Lausanne
Advancing Cancer Research Closer to Home
At AdventHealth, we believe research is not separate from care. We believe the advancements made are what allow us to help our patients feel whole. That commitment is reflected in a new collaboration...
AdventHealth Research Institute Researchers to Present at American Diabetes Association Scientific Sessions
AdventHealth Research Institute (AHRI) is proud to have a strong presence at the American Diabetes Association (ADA) 2026 Scientific Sessions, with multiple investigators and research team members...
Moving More, Managing Better
For people living with type 1 diabetes, managing blood sugar is rarely simple. It’s a daily balancing act involving insulin, food, physical activity, technology and a constant stream of decisions.